Last reviewed · How we verify
Deaminooxytocin (DEMOXYTOCIN)
Deaminooxytocin (generic name: DEMOXYTOCIN) is a demoxytocin drug. It is currently in Phase 2 development.
Deaminooxytocin is thought to work by mimicking the action of oxytocin, a hormone involved in social bonding and childbirth, but with a modified structure that allows it to be a small molecule.
Deaminooxytocin (DEMOXYTOCIN) is a small molecule drug of the demoxytocin class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown. It is not FDA-approved for any indications. The commercial status of Deaminooxytocin is unclear, and it is unknown whether it is patented or available as a generic. Key safety considerations are also unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DEMOXYTOCIN |
|---|---|
| Drug class | demoxytocin |
| Target | Oxytocin receptor |
| Modality | Recombinant protein |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine oxytocin as a key that unlocks a door in the brain, allowing social bonding and childbirth to happen. Deaminooxytocin is like a copy of that key, but with a few tweaks that make it work in a different way. This allows it to potentially treat conditions related to social bonding and childbirth, but more research is needed to understand its effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deaminooxytocin CI brief — competitive landscape report
- Deaminooxytocin updates RSS · CI watch RSS
Frequently asked questions about Deaminooxytocin
What is Deaminooxytocin?
How does Deaminooxytocin work?
What is the generic name of Deaminooxytocin?
What drug class is Deaminooxytocin in?
What development phase is Deaminooxytocin in?
What does Deaminooxytocin target?
Related
- Drug class: All demoxytocin drugs
- Target: All drugs targeting Oxytocin receptor
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing